Compare Braze Inc (BRZE) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Braze Inc vs IDEXX Laboratories, Inc. — how do they compare? Braze Inc trades at $25.87 (market cap $2.95B), while IDEXX Laboratories, Inc. trades at $563.99 (market cap $42.65B). The key difference: IDEXX Laboratories, Inc. is far larger — about 14.5× Braze Inc's market cap, and Braze Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| BRZE | IDXX | |
|---|---|---|
Market Cap | $2.95B | $42.65B |
Sector | Technology | Health |
52-Week High | $36.19 | $766.68 |
52-Week Low | $15.79 | $514.61 |
Enterprise Value | $2.64B | $43.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Braze (BRZE) trades at $26.60, up 5.85% with strong bullish momentum. The stock shows robust revenue growth, increasing from $238M in 2022 to $593M in 2025, though profitability remains negative with a -15.51% net margin. Technical indicators show bullish moving averages but overbought RSI levels. Recent news highlights Goldman Sachs initiation and strong Q1 2027 results with accelerating revenue growth and AI-driven customer engagement tools.
Outlook remains positive with 96% analyst buy ratings and $34.78 consensus target, representing 31% upside. Key risks include persistent losses despite revenue growth and competitive pressures in customer engagement software. The company's AI capabilities and fourth straight quarter of organic revenue acceleration provide growth catalysts, but investors should monitor profitability improvements.
IDXX trades at $564.09, up 0.09% with neutral technical signals. The stock shows strong fundamentals with revenue growth to $4.3B in 2025 and consistent earnings beats. Analyst consensus is bullish (59% Buy) with improving cash flow trends. Recent news highlights AI integration in medical devices and upcoming Q2 2026 earnings.
Outlook remains positive driven by innovation and market leadership in pet healthcare. Risks include high valuation multiples and competitive pressures. Institutional sentiment supports growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
